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Background: The cystic fibrosis transmembrane con-
ductance regulator (CFTR) is a chloride channel that is
activated by cAMP-dependent phosphorylation. CFTR
channel activity is also stimulated by cGMP-dependent
protein kinase and protein kinase C.
Results: Here, we show that CFTR channel activation
by cGMP may also occur directly. In oocytes from one-
third of Xenopus donors, the activation of CFTR by
cGMP averaged 87 % of the level achieved by cAMP.
The currents activated by either cyclic nucleotide dis-
played similar current-voltage relationships, kinetics,
pharmacology and halide selectivity. Sequential stimula-
tion by cAMP and cGMP was not additive, suggesting
that both cyclic nucleotides activate the same channel;
cGMP was one order of magnitude more potent than
cAMP, and its action was insensitive to protein kinase
inhibitors. Analysis of the amino-acid sequence of CFTR
revealed a domain in the amino-terminal portion of the
third cytoplasmic loop that resembles a class of cyclic-
nucleotide-binding domains related to that of the catabo-
lite-gene activator protein, CAP, Two CFTR residues in
this domain - Va397 and Lys420 - were identified
which, when changed to alanine, altered the response to
cGMP independently of the response to cAMP.
Conclusions: We conclude that direct cyclic nucleotide
binding may play a role in channel gating of CFTR. The
cGMP-binding domain may provide a useful target for
pharmacologic intervention in cystic fibrosis.
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Background
The cystic fibrosis transmembrane conductance regulator
(CFTR) [1] is a chloride channel that is activated by
cAMP-dependent protein kinase (PKA) [2,3]. The action
of PKA leads to opening of the channel by the phospho-
rylation of multiple sites on the regulatory domain of
CFTR, located in the distal portion of the third cytoplas-
mic loop [4]. Residual activation occurs despite the
simultaneous removal of ten phosphorylation sites, sug-
gesting that PKA exerts a portion of its effect through
unidentified sites on CFTR or other regulatory proteins
[5]. A role for incremental CFTR phosphorylation in the
gating of its channel by nucleotides has been suggested
recently [6,7]. Protein kinase C (PKC) phosphorylates
CFTR and potentiates channel activation by PKA
[5,8-10], but the mechanism of this potentiation has not
yet been determined.
Cyclic GMP (cGMP) has long been known to stimulate
chloride secretion. In T84 colon carcinoma cells, this
may occur by cross-activation of PKA [11-13]. The
cGMP-dependent protein kinase (PKG) may also play a
role, as endogenous membrane-bound PKG (probably
PKG-II) and exogenous soluble PKG from lung
(PKG-I), but not cGMP plus ATP alone, stimulated
CFTR channel activity in excised patches [14]. In a simi-
lar study of fibroblasts overexpressing CFTR, Berger et
al. [10] also failed to observe activation by cGMP plus
ATP alone. However, in contrast to the findings of Lin et
al. [14], Berger et al. did not observe activation by
exogenous PKG-I. The explanation for this discrepancy
is not clear. In summary, the available evidence suggests
at least two pathways for activation of CFTR by cGMP
- cross-activation of PKA and phosphorylation by PKG.
Non-selective cation channels that exhibit direct,
phosphorylation-independent activation have been iden-
tified in retinal and olfactory sensory receptor cells [15].
Cloning of the genes encoding these channel proteins
[16,17] revealed carboxy-terminal domains similar to a
class of cyclic-nucleotide-binding domains (cNBDs)
related to that of the catabolite gene activator protein
(CAP) [18]. The mechanism of phosphorylation-
independent channel activation has not been extensively
investigated. In a recent study of chimeras constructed
from retinal and olfactory channels, however, Goulding
et al, [19] have suggested that such activation involves
stabilization of the open state of the channel by the
binding of a cyclic nucleotide.
In this study, we compare the response to cAMP and to
cGMP of CFTR expressed in Xenopus oocytes. We show
that inhibition of protein kinase activity does not
diminish the response to cGMP, and that a domain in the
proximal portion of the third cytoplasmic loop resembles
CAP-related cNBDs. Moreover, we demonstrate that
kinase-independent activation by cGMP is selectively
altered by mutation of residues within this domain. We
propose that there is a third cGMP activation pathway, in
which direct binding to a CAP-related cNBD opens the
CFTR channel.
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Results
CFTR is activated by both cAMP and cGMP
Firstly, we examined the electrophysiological profile of
CFTR expressed in Xenopus oocytes (microinjected with
full-length human CFTR cRNA 1-8 days before assay),
with native oocytes as controls. We compared four para-
meters: the time-course of current activation; the time-
dependence of current in response to voltage pulses; the
current-voltage relationships; and the dose-dependence
of current responses to cAMP or cGMP (Fig, 1). In
native oocytes, there was no current activation by either
cyclic nucleotide (n > 3 oocytes per donor from > 10
donor frogs). In oocytes expressing CFTR, current acti-
vated by microinjected cAMP was similar to that
reported previously using mixtures of forskolin plus the
phosphodiesterase inhibitor IBMX (3-isobutyl-l-methyl-
xanthine) plus a permeable cAMP derivative applied to
the bath [20-22]. Current activated by microinjected
cGMP resembled that activated by cAMP in all respects
except dose-dependence (Fig. 1). Current measured over
a range of cyclic nucleotide concentrations displayed
half-maximal activation (K2) at 0.3 + 0.1 tM cGMP
and 4.4 ± 0.5 p.M cAMP, and approached saturation at
10 pIM cGMP and 30 ptM cAMP (Fig. Id). These values
were confirmed in oocytes from different donors. On
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this basis, 10 jM cGMP or 50 I.LM cAMP was employed
as a saturating dose for the experiments described below.
The response to cGMP is dependent on the oocyte donor
and is not additive to the response to cAMP
The current response to cGMP was dependent on the
order of addition of each cyclic nucleotide and on the
donor from which the oocytes were obtained (Fig. 2).
Sequential addition was achieved by double microinjec-
tion using separate pipettes for cAMP and cGMP. When
cAMP was applied first, CFTR current responses dis-
played no additivity in experiments on oocytes from
three different donors (Fig. 2a, traces at left). By contrast,
when cGMP was applied first, the magnitude of the
response was donor-dependent, and the subsequent
application of cAMP elicited additional current (Fig. 2a,
traces at right). As seen from the average values for the
oocytes from each donor, cGMP elicited a submaximal
response which was further stimulated by cAMP to a
value slightly greater than (Fig. 2b,d; p < 0.01; n = 3
oocytes) or equal to (Fig. 2c; p > 0.2; n = 3) that seen
with cAMP alone,
The absence of further current stimulation by cGMP
when cAMP was applied first is consistent with activation
of the same conductance by the two cyclic nucleotides.
Fig, 1. The electrophysiological profile
of CFTR expressed in oocytes is
identical in response to cAMP or cGMP,
but cGMP is a more potent activator. (a)
Current traces from native or CFTR-
injected oocytes in response to cAMP or
cGMP, as indicated. Top trace depicts
the voltage-clamp protocol. (b) Current
response to voltage pulses. Pulses of
1 sec were made from a holding poten-
tial of -20 mV to potentials ranging
from -100 to +50mV in 10 mV
increments. (c) Current-voltage
relationships. Results for (a-c) are repre-
sentative of responses from seven
oocytes in each group, with an average
response to 50 IM cAMP of
1036 : 34 nA and to 10 pM cGMP of
957 ; 30 nA, (d) Dose-response rela-
tion for cAMP and cGMP. Curves were
generated by comparing the response to
single doses in individual oocytes to the
saturating activation level in oocytes
from the same donor assayed on the
same day. The relationships shown are
representative of two (cGMP) or three
(cAMP) complete dose-response curves
(four oocytes per point).
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Fig. 2. The response to cGMP is donor-dependent and is not
additive to the response to cAMP. (a) Effect of sequential addi-
tion of each cyclic nucleotide. Each trace is from a different
oocyte and each horizontal pair of traces (top-to-bottom) is from
a different donor. (b-d) Average maximal CFTR current activated
by cAMP (A), cGMP (G) or their sum, as indicated (n = 3). The
current response to cyclic nucleotide (-Al) in this and all other
figures was measured at -100 mV holding potential. Bar charts
correspond to the top, middle and bottom pairs of traces shown
in (a), respectively. (e) Distribution of cGMP response in oocytes
from 19 donor frogs. Maximal current activated by cGMP alone
(n = 3-5) was expressed as a fraction of maximal current acti-
vated by cAMP alone (n = 3-5) in oocytes from each individual
donor. The 19 paired values were (cGMP/cAMP in nA, standard
error omitted): 150/450, 42/350, 134/354, 213/1257, 84/760,
82/390, 21/520, 1140/1390, 1051/1347, 1520/1600, 176/1350,
368/1673, 571/2283, 336/1600, 1282/1583, 900/2250,
1849/1967, 999/1063, 0/543.
Moreover, the relatively large, but submaximal, responses
elicited by cGMP in the oocytes from the donors shown
in Figure 2c,d were increased only to a level near that of
cAMP alone, not to a level near the sum of both alone.
This is also consistent with activation of the same conduc-
tance. For the oocytes from the donor shown in Figure
2b, however, the current was slightly, but significantly,
greater (by 27 + 1 %; n = 3; p < 0.01) in response to
cGMP plus cAMP, compared with cAMP alone or with
cAMP plus cGMP. This result suggests there may be a
small component of synergistic activation under these
conditions. A somewhat smaller synergistic effect was also
noted for the oocytes from the donor shown in Figure 2d.
The most striking difference between oocytes from
different donors was in the current response to cGMP
alone. When expressed as a percentage of current
activated by cAMP alone, cGMP activated 18 + 2 %
(Fig. 2b, n = 3), 70 ± 21 % (Fig. 2c, n = 3) or 95 3 %
(Fig. 2d, n = 3) in these three donors. The current acti-
vated by cAMP was of similar magnitude in all donors,
suggesting that nearly identical amounts of functional
CFTR was expressed in the oocytes. Examination of
nineteen donors in this way revealed two distinct popula-
tions that were distinguished by average cGMP responses
of 20 3 % (n= 13 donors) and 87+3% (n=6
donors) relative to cAMP (Fig. 2e). In donors from the
former population that gave little or no response to
10 [pM cGMP, dose-response curves at elevated concen-
trations indicated K½ at 58 + 4 u.M cGMP (n = 3 com-
plete dose-response curves; data not shown) and
saturation near 300 .M cGMP. These values are consis-
tent with cross-activation of PKA. The latter population
with the large response to 10 M cGMP was used for
the majority of subsequent experiments.
Pharmacology and anion selectivity are similar for CFTR
currents activated by cAMP and cGMP
To examine further whether current activated by either
cyclic nucleotide is attributable solely to CFTR channels,
the pharmacology and anion selectivity of the two types
of current were compared. First, we applied gliben-
clamide, a KATP channel inhibitor that is the most potent
CFTR inhibitor yet identified [23]. The drug (600 M
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allied externally) inhibited 37 + 3 % (n = 3) or
51 + 15 % (n = 3) of current activated by cAMP
(1569 + 43 nA, n = 8) or cGMP (1314 + 104 nA,
n = 11), respectively (data not shown). Lower concentra-
tions of glibenclamide (up to 100 iM) had no effect,
indicating that it is less potent when applied to CFTR
expressed in oocytes than in other cell systems. The addi-
tion of 1 mM DIDS or 1 mM IAA-94 had no inhibitory
effect in these experiments, in agreement with previous
reports (data not shown).
Next, we examined anion selectivity by lowering the
chloride concentration in the bath from 90 mM to
'n n-/ mine mpt hnI4llSUnn'o rpnlrpmpntt h rSTp ri
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sal potential of current activated by cGMP shifted
23 + 1 mV (n = 4), comparable to the shift of 24 1 mV
(n = 6) observed for current activated by cAMP
(Fig. 3a,b). Both values are close to the shift of 28 mV
predicted from the Nernst equation for a perfectly selec-
tive pathway. Finally, iodide permeability and conduc-
tance measurements were determined as described by
Anderson et al. [24] (Fig. 3c,d). The replacement of chlo-
ride by iodide produced a similar shift in the
current-voltage relationship for cAMP (PI/Pcl was
0.61 + 0.05 and GI/Gcl was 0.52 ± 0.07; n = 6) and
C(UMI (,l/I-CI was U.J T U.u4 and i/Ci was
0.56 + 0.02; n = 3). Thus, both cyclic nucleotides acti-
vated anion-selective channels that were more permeable
to chloride than iodide, a hallmark of CFTR current.
Together, these results suggest that cAMP and cGMP act
exclusively on CFTR channels, and they preclude sec-
ondary effects on other channels, such as the activation of
an endogenous outward rectifier chloride channel
(ORCC, Pi/Pc1 -1.5).
The response to cGMP is insensitive to protein kinase
inhibition
Current activated by the two cyclic nucleotides differed
markedly in sensitivity to protein kinase inhibitors. Addi-
tion of the isoquinolinesulfonamide H-8 (100 ptM), a
broad-spectrum kinase inhibitor, reduced cAMP-acti-
vated current by 57 + 10 %, but had no effect on cGMP-
activated current (Fig. 4). Addition of PKI5 _24 (100 nM),
a selective inhibitor of PKA, reduced cAMP-activated
current by 76 ± 4 %, but also had no effect on cGMP-
activated current. Addition of KT-5823 (1 IzM), a selec-
tive inhibitor of PKG [25], had no effect on CFTR
activation by either cyclic nucleotide. These results sug-
gest that, whereas cAMP activates CFTR only by phos-
phorylation, cGMP may also activate it by a
kinase-independent pathway. One possible explanation
fr ci-rh -rr-xo1hn i ha, A-rfar rl-rl- ti-lrlon-iri _-tJIU SU1.II dLIVdLIUII 15 Uy UIICLL .yCllt. IIC11UICUL1U dL111~.
Fig. 3. Similar anion selectivity suggests that the cAMP- and
cGMP-activated currents are carried solely by CFTR channels. CFTR has a cytosolic domain resembling CAP-related
Representative current-voltage relationships for (a) cAMP and domains that bind cyclic nucleotides
(b) cGMP when bath chloride was lowered from 90 to 30 mM by We compared the amino-acid sequence of CFTR with
replacement with methanesulfonate. Representative current-volt- the cNBD from the retinal rod photoreceptor cyclic-
age relationships for (c) cAMP and (d) cGMP when bath chloride
was lowered from 90 to zero mM by replacement with iodide.
Baseline current-voltage relationships were determined region of similarity was identified in the proximal por-
immediately preceding the addition of cyclic nucleotides. tion of the third cytoplasmic loop of CFTR (Fig. 5).
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Fig. 4. Protein kinase inhibitors reduce the response to cAMP but
not the response to cGMP. Oocytes were untreated (control),
pretreated for 1 h with bath H-8 or KT5823, or microinjected
with PKI 1-3 h prior to activation by 50 pLM cAMP or 5 .M
cGMP. The control values (nA) for the experiments shown (left
to right) were 265 + 75 (n= 5); 470 + 183 (n= 5); 790 + 126
(n = 7); 241 59 (n = 6); 711 ± 68 (n = 6); 205 + 76 (n = 8). For
the displayed experimental values (left to right), n = 5, 5, 6, 8, 5
and 5, respectively. These results are representative of two or
more experiments for each inhibitor and cyclic nucleotide
combination.
This sequence also resembles the amino- and carboxy-
terminal cGMP-binding domains from cGMP-depen-
dent protein kinase and the cAMP-binding domain from
CAP. In CFTR, the region of similarity occurs within a
larger, 82-residue span of unassigned function (positions
351-432) that follows the sixth predicted transmembrane
domain (TM6) and precedes the first nucleotide binding
fold (NBF1; see Fig. 6) [1].
CFTR has 26 % identity to RET over the region shown,
similar to the 16-22 % identity for the other sequences in
the alignment (Fig. 5). Of the seven RET residues mod-
elled to interact directly with cGMP [26], six are identi-
cal or highly conserved in CFTR. To evaluate the role of
these residues in kinase-independent activation by cGMP,
CFTR channels with single amino-acid substitutions at
Fig. 5. The amino-terminal portion of the third cytoplasmic loop
resembles CAP-related cyclic nucleotide binding domains. CFTR
was scanned and aligned with GCG sequence analysis software
(University of Wisconsin). Only a portion of the proposed cNBD
is shown (residues 394-423). The alignment of non-CFTR
sequences is reproduced from Kumar and Weber 26]. The seven
RET residues modelled to interact with cGMP, and their apparent
homologues in CFTR, are underlined and in bold; the homo-
logues in GA, GB and CAP are also in bold. GA, GB: amino- and
carboxy-terminal cGMP-binding domains, respectively, from
cGMP-dependant protein kinase.
these sites were constructed (Table 1). On the basis of the
model for RET, the type of interaction between each
residue and a specific cGMP chemical group could be
predicted.
Single-residue substitutions can alter cGMP-dependent
activation independently of cAMP-dependent activation
We examined the effect of these mutations by expressing
wild-type and mutant channels in oocytes from the same
donor; assays were performed on the same day. Three of
the six channels with a single substitution showed a large
reduction in cAMP-activated current relative to that of
the wild-type channel (wild-type = 1650 + 54 nA;
n = 4-9). The current was only 18 + 13 % (n = 3) of
wild-type level for the mutant channel with the
glutamate at position 407 substituted by glutamine
(mutant E407Q, using the single-letter amino-acid
code); 16 + 3 % (n = 4) for the L408A mutant; and
17 ±+ 1 % (n = 4) for the T421A mutant (data not
shown). Furthermore, when three residues at positions
406-408 were simultaneously deleted (mutant GEL-),
the current was only 4 2 % (n = 4) of the wild-type
level (data not shown). A double substitution mutant
(E407Q plus E403D) produced 63 + 8 % (n = 9) wild-
type channel current (wild-type =2250 + 195 nA;
n = 5; data not shown). Together, these results indicate
that the substitution of one or two residues, or a small
Fig. 6. CFTR domain map incorporating the proposed cyclic
nucleotide binding domain (cNBD) in the third cytoplasmic loop.
NBF, nucleotide-binding fold; R, regulatory domain [1].
397 406 420
CFTR 394 MENVTAFWEEG--FGEL-FEKAKQ-NNNNRKTSN
RET 530 ITQEVVL-SDGSYFGEISILNIKGSKAGNRRTAN
GA 153 GVKLCTM-GPGKVFGELAILYN------CTRTAT
GB 277 PVFLRTL-GKGDWFGEKALQGE------DVRTAN
CAP 58 EMILSYL-NQGDFIGELGLFEE-----GQERSAW
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suggesting that the mutants were processed normally and
delivered to the plasma membrane (Fig. 7). Experiments
on the activation of wild-type CFTR and these three
mutants by cGMP were performed in the simultaneous
presence of PKI and KT-5823 to eliminate protein
kinase activities. The G406A mutant responded nor-
mally to cGMP (Fig. 7a,c). However, cGMP activation
of the other two mutants differed from the wild-type
response. The V397A mutant displayed a cGMP
response that was enhanced by 66 + 19 % (n = 5;
p < 0.05) relative to the wild-type channel (Fig. 7a,b).
The K420A substitution, which produced the largest
effect, reduced the cGMP response by 75 ± 6 % (n = 4;
p < 0.005; Fig. 7a,c) compared with the wild-type chan-
nel. This result was confirmed in an identical experiment
in which the cGMP response was reduced 84 ± 5 %
(n = 5; p < 0.001) compared with the wild-type channel
(1250 + 124 nA).
Discussion
Donor-dependence of direct activation
The observed distribution in the magnitude of direct
activation by cGMP between oocytes from different
donors, together with the failure of other studies to
report such a direct effect, suggests that this pathway may
be inoperative under many experimental conditions. At
least three factors could contribute to the donor-
dependence of direct activation. First, differences in the
activity of cyclic nucleotide phosphodiesterase (PDE)
may exist among donors. Oocytes express more than one
PDE [27], but their individual PDE types have not been
characterized extensively [28]. Hydrolysis of cGMP may
occur in crude homogenates but not in intact oocytes
[29], and hydrolysis of cAMP is stimulated by insulin and
insulin-like growth factor 1 [30], indicating that oocyte
PDEs are under hormonal regulation. In guinea-pig
ventricular myocytes, cGMP enhances submaximally-
stimulated catecholamine-induced chloride current
through milrinone-sensitive cGMP-inhibited PDE (type
III) [31]. In the present study, however, a role for PDE
type III can be precluded as the PKA inhibitors H-8 and
PKI did not diminish activation by cGMP.
Fig. 7. Key residue substitutions alter the response to cGMP inde-
pendently of the response to cAMP. (a) Current traces from wild-
type CFTR or single-residue substitution mutants as indicated. (b)
Effect of V397A substitution compared with the wild-type CFTR
(n = 5). (c) Effect of G406A or K420A substitutions compared
with wild-type CFTR (n = 4).
deletion, can have a range of negative effects on cAMP-
activated current. For this group of mutations, we were
unable to distinguish between an effect on gating by
cAMP and the introduction of a defect in the processing
of the protein.
The three other single-substitution mutants (V397A,
G406A and K420A) produced functional channels that
responded to cAMP in a manner identical to wild type,
Direct activation may also be modulated by
phosphorylation. For example, the affinity of RET for
cyclic nucleotides appears to be modulated by phos-
phatase activity [32], and dual control of channel activity
by phosphorylation and direct effects have been
described for the nonselective cation channel from renal
inner medulla [33,34]. However, the only consensus
PKA site within the CFTR cNBD - serine at position
422 - is an unlikely candidate for phosphorylation as it
is a poor substrate for PKA in vitro [9]. This does not
preclude the possibility of phosphorylation at cryptic
sites by PKA or other kinases. Cryptic phosphorylation
activates CFTR [5], and it will be important to deter-
mine the relationship between cryptic phosphorylation
and direct activation.
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Finally, for the olfactory sensory channel (OLF), the
presence of bound calmodulin (CaM) shifts the cGMP
activation curve to the right by one full order of magni-
tude [35]. Thus, it will be interesting to determine
whether CaM influences CFTR activation by the direct
pathway. Other possibilities, not considered here, may
account in whole, or in part, for the donor-dependence
of direct activation.
Relation to other cyclic-nucleotide-binding domains
Cyclic-nucleotide-binding domains appear in a variety of
proteins having diverse functions [18]. The cNBDs iden-
tified are highly degenerate at the primary sequence level.
As only one crystal structure of such a domain has been
available, gaps exist in our knowledge of the contacts that
individual residues make with the cyclic nucleotides. The
CFTR residues between TM6 and NBF1 span a region
large enough to form the eight-stranded antiparallel 
roll observed in the crystal structure of CAP [36,37]. The
two most conserved 3 strands (defined here as having
one-third or more of all strand residues encoded by three
or fewer possibilities) in an alignment of 24 sequences are
(2 and (37 [18]. These two strands may correspond to
residues 373-378 and 418-423 in CFTR. The invariant
glycine residues found at the ends of the 33 strand in
CAP are not conserved in CFTR. The amino and car-
boxyl termini, which are the most degenerate portions of
domains identified previously, may be contributed to by
part of TM6 and NBF1, respectively, perhaps providing
links to the conduction pathway and other regulatory
domains. (We note with interest that a second
CAP-related structure has been solved recently [38]).
Our mutagenesis experiments address the likelihood of
three potential sites for cGMP contact. The substitution
of the valine at position 397 for an alanine resulted in a
mildly enhanced cGMP response - opposite to the pre-
dicted result. As the smaller hydrophobic surface pro-
vided by alanine was stimulatory, valine is unlikely to
make an important hydrophobic interaction with the
guanine ring of cGMP. Uncertainty surrounding purine
contact sites is well noted [18]. For example, the crystal
structure of CAP indicates cAMP binding in the anti
conformation, whereas solution nuclear magnetic reso-
nance studies with CAP and kinases suggest binding in
the syn conformation. Although our experiment indi-
cates that valine 397 is in an important location, it may
require detailed structural information to determine its
precise role in activation by cGMP.
The substitution of an alanine for the glycine at position
406, which replaced the minimal proton with a bulkier
methyl group, had no effect on activation by cGMP As
this glycine is invariant, the substitution was predicted to
be disruptive. However, a hydrogen-bond between the
ribose 2'-hydroxyl group and the amino group of this
residue's peptide bond could, in principle, occur with any
substitution tolerated by the rest of the domain. It would
be of interest to compare the effects of substitutions at
this position in analogous domains from other proteins.
The substitution of an alanine for the lysine at position
420 was predicted to disrupt an ionic interaction with
exocyclic phosphate oxygen, resulting in reduced activa-
tion by cGMP. We observed a profoundly diminished
response, which suggests that a charge interaction at this
position plays an important role in direct activation by
cGMP. CFTR appears unique in that lysine contributes
the positive charge, instead of the arginine residue
encountered in all other domains. Further experiments
will be required to determine the cyclic-nucleotide
specificity and binding activity of this domain.
The available evidence suggests that CFTR functions as a
monomer [39], whereas CAP and kinases are known to
function as dimers. A truncated CFTR molecule engi-
neered to terminate at residue 836 (of the native 1480
residues) produced a homomultimer (probably a homo-
dimer) [40], suggesting that the internal symmetry of
intact CFTR may replace dimer formation. However,
the analogous region in the second half of CFTR
(residues 1151-1218) does not resemble a CAP-related
cNBD, suggesting that each full-length CFTR monomer
would bind only one molecule of cGMP. By compari-
son, the subunit stoichiometry of sensory channels has
not been determined, but is presumed to be tetrameric,
similar to that of voltage-dependent potassium channels.
Another class of channels, permeable to potassium and
calcium ions, display voltage-dependent gating which
may be modified directly by cAMP. The ether-a-go-go
gene product, Eag, and other related channels from
Drosophila to mammals have a putative cNBD in the car-
boxy-terminal portion of the protein [41,42]. These
cNBDs do not have a threonine residue corresponding to
that present in RET, PKGs and CFTR (see alignment in
[43] and Fig. 5), consistent with the absence of cGMP
effects on the Eag current [41].
Physiological role and significance of direct activation in
CFTR channel gating
The presence of a cNBD in CFTR is unexpected
because of the dominant role that cross-activation appears
to play in secretion stimulated by cGMP. The domain
may provide a pathway for activation at a level of cGMP
below that needed for cross-activation. Previously, a two-
fold increase in measurable cGMP was observed to have
no effect on trans-epithelial secretion [441. That result is
not directly comparable to the present study, however, as
the concentration of cGMP in the cells expressing
CFTR was not determined. Alternatively, the domain
may function only under certain basal conditions. Studies
mentioned previously indicate that phosphorylation-
dependent activation is complex. Further investigation
will be required to determine whether the cNBD
activates alone, or in conjunction with other gating
mechanisms of this highly regulated channel.
In airway epithelial cells, evidence exists for the expres-
sion of nitric oxide synthase [45,46], soluble guanylate
cyclase and C-type natriuretic peptide receptor [47],
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suggesting at least two pathways for the generation of
cGMP in this tissue. However, a cGMP effector target
has not been clearly identified. Most expression of
CFTR occurs in submucosal glands, notably serous
epithelial cells of secretory tubules and not surface
epithelium [48]. It is of critical importance to define fur-
ther the distribution of messengers and effectors among
the myriad cell types in the lung, in order to resolve the
role of cGMP in the activation of airway CFTR.
None of the thirty most-common mutations associated
with the cystic fibrosis disease occurs within this 82-
residue region [49]. As many mutant CFTRs display
some channel activity (reviewed in [3]), pharmacological
activation of this domain may be beneficial. Understand-
ing the range of cGMP effects that have been reported
therefore represents a major hurdle before such an
approach would become feasible. Nevertheless, if mutant
protein trapped within intracellular compartments can be
retargeted to the plasma membrane (for example, see the
study by Stanton and coworkers [50]), then drugs
designed for direct activation would provide an alterna-
tive to less-specific compounds that act by the global
stimulation of signaling pathways.
Conclusions
The study described here demonstrates a new pathway
for the activation of CFTR. Experiments with protein
kinase inhibitors indicate that cGMP can activate the
channel by a kinase-independent mechanism. Analysis of
the amino-acid sequence of CFTR reveals that the
amino-terminal region of the third cytoplasmic loop
resembles known cyclic-nucleotide-binding domains.
Two point mutations in this domain, predicted to disrupt
direct contact with cGMP, alter the response to cGMP
with no effect on the response to cAMP. Together, the
results support the identification of a site for direct
cyclic-nucleotide activation of CFTR. This domain may
provide a useful target for pharmacological intervention
in cystic fibrosis.
Materials and methods
Oocytes
Frogs (X. laevis) were obtained from Xenopus I (Ann Arbor,
Michigan). Oocytes were prepared and maintained at 18 C in
modified Barth's saline (MBS) supplemented with antibiotics as
described previously [51]. Oocytes of 1 1.2 mm diameter were
used. Reported concentrations are based on a free intracellular
volume of 500 nl, to account for abundant yolk granules in the
vegetal hemisphere.
Expression of CFTR
Full-length human CFTR cDNA [52], flanked by the 5'
untranslated region from the Xenopus 3-globin gene and a 3'
poly A23C3( 1tail, was transcribed from pBluescript (Stratagene)
using T7 RNA polymerase according to manufacturer's recom-
mendations (Promega). The cRNA (5 ng per oocyte) was
injected into oocytes 1-8 days prior to assay for CFTR current.
Electrophysiology
Technical details were as described previously [51]. All record-
ings were performed in MBS, which contained 90.4 mM Na+ ,
1 mM K+ , 0.74 mM Ca2 +, 0.82 mM Mg2 + , 89.8 mM C1-,
2.4 mM HCO3-, 0.82 mM s042-, 0.66 mM NO 3- and
10 mM HEPES acid (pH 7.4 with NaOH), except as indicated
in the text.
Values reported in the text or displayed in bar graphs are
means + standard error for the change in response to cyclic
nucleotides measured at a holding potential of-100 mV (-AI).
The number (n) of observations reported refers to oocytes
unless frogs (donors) are mentioned. Statistical comparisons
were performed using Student's t-test. All comparisons
between control and experimental groups were made on
oocytes from the same donor assayed on the same day. Only
natural cyclic nucleotides were used, in order to approximate
closely physiological conditions, and to avoid the possibility
that derivatives may behave differently for direct activation.
For sequential addition experiments, each cyclic nucleotide
was injected in a 25 nl volume to maintain the total added vol-
ume at 50 nl. Saturating doses (50 FtM cAMP and 10 IpM
cGMP) were employed in all experiments, except that 5 aM
cGMP was used for kinase inhibitor studies. Permeability and
conductance ratios were calculated as described [24].
Mutagenesis
The 1 kb CFTR XbaI-SphI restriction fragment was excised
from the transcription vector, cloned into pALTER (Pro-
mega), mutagenized using oligonucleotides with silent restric-
tion sites to facilitate screening, and transferred back to the
original vector for sequencing in both directions. Mutant
CFTR was expressed in oocytes as above.
Reagents
PKI was obtained from Peninsula, KT5823 from Kamiya, H-8
from Research Biochemicals International, and cyclic
nucleotides from Sigma or Calbiochem. All other reagents
were from Sigma, Boehringer Mannheim, Promega or New
England Biolabs.
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